Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.
Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.